keyword
https://read.qxmd.com/read/38617071/leukocytoclastic-vasculitis-in-a-patient-with-ankylosing-spondylitis-a-case-report
#21
Alireza Khabbazi, Sepideh Tahsini Tekantapeh, Cyrus Asadzadeh, Amir Vahedi
KEY CLINICAL MESSAGE: Although the concurrent occurrence of vasculitis with AS is uncommon, when patients diagnosed with AS exhibit symptoms including skin petechiae, purpura, abdominal discomfort, malaise, elevated ESR, and reduced complement levels, vigilant monitoring for vasculitis is advisable following the exclusion of secondary vasculitis triggers such as malignancies, infections, and pharmaceutical agents. ABSTRACT: The primary characteristic of ankylosing spondylitis (AS) involves inflammation occurring within the sacroiliac joint and the spine, leading to destruction and eventual ankylosis...
April 2024: Clinical Case Reports
https://read.qxmd.com/read/38616859/development-of-a-multiplex-polymerase-chain-reaction-assay-for-detection-of-hepatitis-c-virus-hepatitis-b-virus-and-human-immunodeficiency-virus-1
#22
JOURNAL ARTICLE
Waleed Abdelgaber Nemr, Radwan K Nashwa
BACKGROUND: Hepatitis C virus (HCV), hepatitis B virus (HBV), and human immunodeficiency virus 1 (HIV-1) are the most epidemic blood-borne viruses, posing threats to human health and causing economic losses to nations for combating the infection transmission. The diagnostic methodologies that depend on the detection of viral nucleic acids are much more expensive, but they are more accurate than serological testing. AIM: To develop a rapid, cost-effective, and accurate diagnostic multiplex polymerase chain reaction (PCR) assay for simultaneous detection of HCV, HBV, and HIV-1...
March 25, 2024: World Journal of Virology
https://read.qxmd.com/read/38616852/outcomes-of-liver-resection-in-hepatitis-c-virus-related-intrahepatic-cholangiocarcinoma-a-systematic-review-and-meta-analysis
#23
JOURNAL ARTICLE
Feng Yi Cheo, Kai Siang Chan, Vishal G Shelat
BACKGROUND: Cholangiocarcinoma is the second most common primary liver malignancy. Its incidence and mortality rates have been increasing in recent years. Hepatitis C virus (HCV) infection is a risk factor for development of cirrhosis and cholangiocarcinoma. Currently, surgical resection remains the only curative treatment option for cholangiocarcinoma. We aim to study the impact of HCV infection on outcomes of liver resection (LR) in intrahepatic cholangiocarcinoma (ICC). AIM: To study the outcomes of curative resection of ICC in patients with HCV ( i...
March 25, 2024: World Journal of Virology
https://read.qxmd.com/read/38616850/global-trends-in-hepatitis-c-related-hepatocellular-carcinoma-mortality-a-public-database-analysis-1999-2019
#24
JOURNAL ARTICLE
Hassam Ali, Fnu Vikash, Vishali Moond, Fatima Khalid, Abdur Rehman Jamil, Dushyant Singh Dahiya, Amir Humza Sohail, Manesh Kumar Gangwani, Pratik Patel, Sanjaya K Satapathy
BACKGROUND: Hepatitis C is the leading cause of chronic liver disease worldwide and it significantly contributes to the burden of hepatocellular carcinoma (HCC). However, there are marked variations in the incidence and mortality rates of HCC across different geographical regions. With the advent of new widely available treatment modalities, such as direct-acting antivirals, it is becoming increasingly imperative to understand the temporal and geographical trends in HCC mortality associated with Hepatitis C...
March 25, 2024: World Journal of Virology
https://read.qxmd.com/read/38616711/association-between-hepatitis-c-virus-genotype-4-and-renal-cell-carcinoma-molecular-and-virological-studies
#25
JOURNAL ARTICLE
Asmaa E Ahmed, Hassan Abol-Enein, Adel A El-Morsi, Ahmed S El-Hefnawy, Ashraf A Elsayed, Sherry Khater, Abdelwahab Hashem, Abdel-Rahman N Zekri, Samia A Haroun, Ahmed A Shokeir, Amira Awadalla
Hepatitis C virus (HCV) is the most common infection worldwide. The correlation between HCV and renal cell carcinoma (RCC) is still mysterious. Therefore, the relationship between HCV and RCC was investigated. The study included 100 patients with RCC; 32 with HCV infection, and 68 without HCV infection. Expressions of viral proteins (NS3 and NS5A) were tested using an immune electron-microscope (IEM) and immunohistochemistry (IHC). IHC and quantitative real time-PCR investigated the presentation of human proteins TP53 and p21 genes...
April 15, 2024: Journal of Basic Microbiology
https://read.qxmd.com/read/38615268/the-burden-of-hcv-among-prevalent-hemodialysis-patients-after-the-national-egyptian-hcv-eradication-program
#26
MULTICENTER STUDY
Iman I Sarhan, Magdy M ELSharkawy, Maha M El Gaafary, Doaa M T Hendam, Khaled Gouda
In the first phase of its treatment program, Egypt aimed to treat 250,000 people annually until 2020, thereby reducing the number of viremic patients and limiting hepatitis C virus (HCV) transmission. Egypt strives to eradicate HCV and HCV-associated morbidity by 2030. This study aimed to determine the prevalence of HCV infection among end-stage renal disease patients and the reasons for non-treatment among those offered free medication. This multi-center cross-sectional study was conducted during the period from November 2022 to April 2023...
April 2024: Egyptian Journal of Immunology
https://read.qxmd.com/read/38615267/serum-microrna-16-as-a-potential-biomarker-for-hcv-induced-hepato-cellular-carcinoma-in-egyptian-patients
#27
JOURNAL ARTICLE
Amr T El Hawary, Fedaa Nabil, Ramy El Hendawy, Haytham K A Mahrous, Ghada A AbdelHamid, Mahmoud Amer
Hepatocellular carcinoma (HCC) is one of the most prevalent cancers in the world. Two risk factors that cause 80-90% of HCC cases globally are chronic infection with hepatitis B virus (HBV) and hepatitis C virus (HCV). The diagnostic value of circulating microRNAs (miRNAs) in numerous tumors has been described. Our research assessed microRNA-16 (miR-16) as a novel biomarker in patients with HCV-induced HCC. The study included three groups. Group 1 included 55 individuals with cirrhosis caused by liver HCV infection in addition to HCC...
April 2024: Egyptian Journal of Immunology
https://read.qxmd.com/read/38615235/clinical-significance-of-viral-markers-testing-by-elisa-and-individual-donation-nucleic-acid-testing-id-nat-for-blood-screening-in-blood-bank-single-center-study-in-egypt
#28
JOURNAL ARTICLE
Fadia M Attia, Ahmed M Farouk, Shaymaa A Abdelhady
Prevention of transfusion-transmitted viral infections and insurance of safe blood transfusion are the main goals of all blood banks worldwide. Despite the high sensitivity and specificity of currently used enzyme linked immunosorbent assay (ELISA) for hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) testing, viral transmission could still occur during the window period. Introducing viral individual donation nucleic acid testing (ID-NAT) can greatly decrease such risk providing an additional layer in securing blood transfusion...
April 2024: Egyptian Journal of Immunology
https://read.qxmd.com/read/38614633/efficacy-of-assisted-partner-services-for-people-who-inject-drugs-in-kenya-to-identify-partners-living-with-hiv-and-hepatitis-c-virus-infection-a-prospective-cohort-study
#29
JOURNAL ARTICLE
Aliza Monroe-Wise, Loice Mbogo, Betsy Sambai, Natasha Ludwig-Barron, Brandon L Guthrie, David Bukusi, Bhavna H Chohan, Sarah Masyuko, John Scott, Emily Juma, Paul Macharia, Hanley Kingston, William Sinkele, Esther Gitau, Rose Bosire, Helgar Musyoki, Joshua Herbeck, Carey Farquhar
BACKGROUND: People who inject drugs are at increased risk of both HIV and hepatitis C virus (HCV) infections but face barriers to testing and engagement in care. Assisted partner services are effective in locating people with HIV but are understudied among people who inject drugs. We assessed whether assisted partner services could be used to find, test for HIV and HCV infections, and link to care the partners of people who inject drugs in Kenya. METHODS: In this prospective study at eight sites offering harm-reduction services in Kenya, we enrolled people aged 18 years or older who inject drugs and were living with HIV (index participants) between Feb 27, 2018, and Nov 1, 2021...
May 2024: Lancet Global Health
https://read.qxmd.com/read/38614281/real-world-performance-of-the-neumodx%C3%A2-hcv-quant-test-for-quantification-of-hepatitis-c-virus-hcv-rna
#30
JOURNAL ARTICLE
Nadine Lübke, Andreas Walker, Martin Obermeier, Jennifer Camdereli, Martha Paluschinski, Lara Walotka, Anna-Kathrin Schupp, Inga Tometten, Sandra Hauka, Eva Heger, Jörg Timm
Quantification of hepatitis C virus (HCV)-RNA in serum or plasma samples is an essential parameter in HCV diagnostics. Here, the NeuMoDx™Molecular System (Qiagen) was tested for the most common HCV genotypes and compared to the cobas c6800 system (Roche). HCV-RNA from 131 plasma/serum samples from chronically infected patients was determined in parallel on the NeuMoDx and c6800 systems. Linearity was analysed using the four most common HCV genotypes (1-4) in our cohort. The coefficient of variation (CV) within (intra-assay) and between (inter-assay) runs was calculated based on HCV-RNA concentration...
April 11, 2024: Journal of Virological Methods
https://read.qxmd.com/read/38613690/dynamic-change-of-metabolic-dysfunction-associated-steatotic-liver-disease-in-patients-with-hepatitis-c-virus-infection-after-achieving-sustained-virologic-response-with-direct-acting-antivirals
#31
JOURNAL ARTICLE
Chen-Hua Liu, Yu-Ping Chang, Yu-Jen Fang, Pin-Nan Cheng, Chi-Yi Chen, Wei-Yu Kao, Chih-Lin Lin, Sheng-Shun Yang, Yu-Lueng Shih, Cheng-Yuan Peng, Ming-Chang Tsai, Shang-Chin Huang, Tung-Hung Su, Tai-Chung Tseng, Chun-Jen Liu, Pei-Jer Chen, Jia-Horng Kao
BACKGROUND: Information on the dynamics of metabolic dysfunction-associated steatotic liver disease (MASLD) among hepatitis C virus patients achieving sustained virologic response (SVR12 ) with direct-acting antivirals (DAAs) is limited. METHODS: We enrolled 1512 eligible participants in this prospective study. MASLD was defined by a controlled attenuation parameter (CAP) of ≥248 dB/m utilizing vibration-controlled transient elastography in conjunction with presence of  ≥1 cardiometabolic risk factor...
April 13, 2024: Journal of Gastroenterology
https://read.qxmd.com/read/38610115/elevation-of-s2-bound-%C3%AE-1-acid-glycoprotein-is-associated-with-chronic-hepatitis-c-virus-infection-and-hepatocellular-carcinoma
#32
JOURNAL ARTICLE
Carlos Oltmanns, Birgit Bremer, Laura Kusche, Per Stål, Robin Zenlander, Jan Tauwaldt, Ingvar Rydén, Peter Påhlsson, Markus Cornberg, Heiner Wedemeyer
There is an urgent need for new high-quality markers for the early detection of hepatocellular carcinoma (HCC). Åström et al. suggested that S2-bound α1-acid glycoprotein (AGP) might be a promising marker. Consequently, we evaluated the predictive advantage of S2-bound AGP in the early detection of HCC. In a retrospective case-control study of patients chronically infected with hepatitis C virus (HCV) and treated with direct-acting antiviral agents (n = 93), we measured S2-bound AGP using the HepaCheC® ELISA kit (Glycobond AB, Linköping, SE) at the start of treatment, end of treatment and follow-up (maximum: 78 months)...
April 12, 2024: Journal of Viral Hepatitis
https://read.qxmd.com/read/38608357/factors-associated-with-hepatitis-c-testing-treatment-and-current-hepatitis-c-infection-among-men-and-women-who-inject-drugs-the-ethos-engage-study
#33
JOURNAL ARTICLE
Heather Valerio, Alison D Marshall, Anna Conway, Carla Treloar, Lisa Carter, Marianne Martinello, Charles Henderson, Janaki Amin, Phillip Read, David Silk, Louisa Degenhardt, Bianca Prain, Maryam Alavi, Gregory J Dore, Jason Grebely
BACKGROUND: Evaluating gender-specific trends in hepatitis C virus (HCV) treatment uptake among men and women who inject drugs is crucial for ensuring equitable progress towards HCV elimination. This study aimed to quantify differences in testing, treatment, and current HCV infection between men and women who inject drugs. METHOD: ETHOS Engage is an observational cohort study of people who inject drugs attending drug treatment clinics and needle and syringe programs in Australia recruited from May 2018-September 2019 (wave 1) and November 2019-April 2021 (wave 2)...
April 11, 2024: International Journal on Drug Policy
https://read.qxmd.com/read/38607595/transfusion-transmitted-infections
#34
REVIEW
Han Joo Kim, Dae-Hyun Ko
The risk of transfusion-transmitted infection (TTI) has always existed because transfused blood products are biological materials derived from humans. To prevent TTIs, screening strategies have been developed for various infectious diseases, such as hepatitis B virus, hepatitis C virus, and human immunodeficiency virus, contributing significantly to reducing TTI globally. Nevertheless, septic transfusion reactions (STRs) due to bacterial contamination remain an unresolved issue. Various infectious diseases can be transmitted through blood products, and preventive and selective screening strategies have been applied across different regions...
April 12, 2024: Blood Research
https://read.qxmd.com/read/38605149/predictors-of-severe-hepatotoxicity-among-retroviral-infected-adults-on-haart-regimen-in-ilubabor-zone-southwest-ethiopia
#35
JOURNAL ARTICLE
Tefera Darge, Alemayehu Babusha, Dessalegn Chilo, Abebe Dukessa, Sisay Teferi
Nearly half of the deaths among hospitalized human immuno deficiency virus-infected patients in the highly active antiretroviral therapy era have been attributed to liver disease. This may range from an asymptomatic mild increase of liver enzymes to cirrhosis and liver failure. Different works of literature elucidated both retroviral infection and the adverse effects of highly active antiretroviral therapy as a cause of hepatotoxicity. Individual adaptations to medications and environmental exposures, shaped by cultural norms and genetic predispositions, could potentially modulate the risk and progression of liver disease in this population...
April 11, 2024: Scientific Reports
https://read.qxmd.com/read/38604387/b-cell-characteristics-define-hcv-reinfection-outcome
#36
JOURNAL ARTICLE
Alexander P Underwood, Money Gupta, Bing-Ru Wu, Auda A Eltahla, Irene Boo, Jing Jing Wang, David Agapiou, Arunasingam Abayasingam, Arnold Reynaldi, Elizabeth Keoshkerian, Yanran Zhao, Nicholas Brasher, Melanie R Walker, Jens Bukh, Lisa Maher, Tom Gordon, Miles P Davenport, Fabio Luciani, Heidi E Drummer, Andrew R Lloyd, Rowena A Bull
BACKGROUND AND AIMS: In individuals highly exposed to hepatitis C virus (HCV), reinfection is common, suggesting that natural development of sterilising immunity is difficult. In those that are reinfected, some will develop a persistent infection, while a small proportion repeatedly clear the virus, suggesting natural protection is possible. The aim of this study was to characterise immune responses associated with rapid natural clearance of HCV reinfection. METHODS: Broad neutralising antibodies (BnAbs) and Envelope 2 (E2)-specific memory B cell (MBCs) responses were examined longitudinally in 15 subjects with varied reinfection outcomes...
April 9, 2024: Journal of Hepatology
https://read.qxmd.com/read/38602340/changes-in-clinical-outcomes-in-japanese-patients-with-hepatocellular-carcinoma-due-to-hepatitis-c-virus-following-the-development-of-direct-acting-antiviral-agents
#37
JOURNAL ARTICLE
Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, Kazuya Kariyama, Ei Itobayashi, Kunihiko Tsuji, Toru Ishikawa, Hidenori Toyoda, Takeshi Hatanaka, Satoru Kakizaki, Atsushi Naganuma, Fujimasa Tada, Hironori Tanaka, Shinichiro Nakamura, Kazuhiro Nouso, Kazunari Tanaka, Takashi Kumada
BACKGROUND AND AIM: Direct-acting antivirals (DAAs) have been accessible in Japan since 2014. The aim of this study is to compare how the prognosis of patients with hepatitis C virus (HCV)-associated hepatocellular carcinoma (HCV-HCC) changed before and after DAA development. METHODS: A retrospective analysis of 1949 Japanese HCV-HCC patients from January 2000 to January 2023 categorized them into pre-DAA (before 2013, n = 1169) and post-DAA (after 2014, n = 780) groups...
April 11, 2024: Journal of Gastroenterology and Hepatology
https://read.qxmd.com/read/38596502/shear-wave-elastography-to-predict-hepatocellular-carcinoma-after-hepatitis-c-virus-eradication-a-systematic-review-and-meta-analysis
#38
JOURNAL ARTICLE
Giorgio Esposto, Paolo Santini, Linda Galasso, Irene Mignini, Maria Elena Ainora, Antonio Gasbarrini, Maria Assunta Zocco
BACKGROUND: Direct-acting antiviral agents (DAAs) are highly effective treatment for chronic hepatitis C (CHC) with a significant rate of sustained virologic response (SVR). The achievement of SVR is crucial to prevent additional liver damage and slow down fibrosis progression. The assessment of fibrosis degree can be performed with transient elastography, magnetic resonance elastography or shear-wave elastography (SWE). Liver elastography could function as a predictor for hepatocellular carcinoma (HCC) in CHC patients treated with DAAs...
March 14, 2024: World Journal of Gastroenterology: WJG
https://read.qxmd.com/read/38594686/knowledge-attitude-and-practice-towards-hepatitis-b-and-c-virus-infection-and-associated-factors-among-adults-living-at-selected-woredas-in-gamo-zone-southern-ethiopia-a-cross-sectional-study
#39
JOURNAL ARTICLE
Tamiru Chonka, Gesila Endashaw, Eshetu Zerihun, Bereket Beyene Shashamo
BACKGROUND: Hepatitis is an inflammation of the liver tissue. It is one of the serious public health problems. Though an individuals' knowledge, attitude, and practice level is very vital in order to ensure the control of its adverse health impacts, little is known regarding these issues in the community level. Therefore, this study was aimed to assess knowledge, attitude, and practice towards hepatitis B and C virus infection and associated factors among adults living at selected woredas in Gamo Zone, Southern Ethiopia...
April 9, 2024: BMC Public Health
https://read.qxmd.com/read/38593518/slicing-through-silos-development-and-evaluation-of-a-hospital-based-telehealth-hepatitis-c-virus-treatment-program
#40
JOURNAL ARTICLE
J Babiarz, H Ryu, C Williams, Y Ham, J Rivera Sarti, X A Levander
BACKGROUND: There exist many barriers to hepatitis C virus (HCV) treatment for those with substance use disorder (SUD) or who lack access to routine medical care. A hospital-based telehealth program was developed to provide treatment opportunities for hospitalized patients living with HCV. METHODS: This single site prospective cohort study conducted from July 2022 to March 2023 aimed to measure linkage to care with an HCV clinician and initiation of HCV treatment in hospitalized patients...
April 8, 2024: International Journal on Drug Policy
keyword
keyword
18361
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.